-
2024-517247-31-00
5
2025-07-07
Newly Diagnosed Higher Risk Myelodysplastic Syndrome
-
2024-516020-33-00
4
2025-06-26
Grave’s Disease
-
2024-518469-84-00
4
2025-06-20
Colorectal cancer
-
2024-517992-19-00
1
2025-06-11
C3 glomerulopathy (C3G)
-
2024-511534-12-00
7
2025-06-10
Advanced or Metastatic Solid Tumours
-
2024-513122-27-00
5
2025-06-10
Unresectable, Locally Advanced or Metastatic HER2 positive Gastric or
-
2024-517458-90-00
5
2025-06-06
Chronic obstructive pulmonary disease (COPD)
-
2023-509391-42-00
11
2025-06-02
Chron's Disease
-
2024-515280-60-00
5
2025-05-29
Lupus nephritis
-
2024-514341-10-00
1
2025-05-27
Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractor
-
2023-506817-23-01
5
2025-05-23
Metastatic hormone naïve prostate cancer (mHNPC)
-
2024-514937-39-00
5
2025-05-20
Dravet Syndrome
-
2024-514953-31-00
4
2025-05-20
Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
-
2024-515984-68-00
4
2025-05-20
Non-small cell lung cancer (NSCLC)
-
2024-516615-25-00
1
2025-05-14
hepatocellular carcinoma (HCC)
-
2024-519498-20-00
9
2025-05-13
Acute Myeloid Leukaemia (AML)/higher-risk Myelodysplastic Syndrome (MD
-
2023-510155-37-00
5
2025-05-08
Hypomethylating agent (HMA) naive myelodysplastic syndromes
Myelodyspl
-
2023-506460-14-00
5
2025-05-07
Chronic kidney disease (CKD) and hypertension.
-
2024-511915-21-01
1
2025-05-05
advanced or metastasic triple-negative breast cancer
-
2024-515053-21-00
4
2025-04-30
Plasma cell leukaemia
-
2024-515279-37-00
5
2025-04-17
Relapsed or Refractory and Lenalidomide exposed Multiple Myeloma
-
2023-508112-35-00
4
2025-04-15
ROS1-positive non-small cell lung cancer (NSCLC) with active brain met
-
2023-504180-16-00
5
2025-04-07
Advanced Breast Cancer
-
2023-507613-10-01
7
2025-03-31
Active Systemic Lupus Erythematosus;Systemic lupus erythematosus (SLE)